BIOLOGICAL · Unmapped registry intervention
Blood samples for PK
Find medicine records ·
Find other trials using this name
Clinical trial
Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer
NCT07490509
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
OTHER · Unmapped registry intervention
Questionnaire
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedPharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer
Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE4
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Abemaciclibunresolved
Abemaciclib-related Diarrheaunresolved
Breast Cancerverified · MONDO: breast cancer
Interventions
Blood samples for PKBIOLOGICAL
QuestionnaireOTHER
Sponsors & collaborators
Poitiers University Hospitallead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07490509 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.